Login
COLLEGIUM PHARMACEUTICAL, INC logo

COLLEGIUM PHARMACEUTICAL, INC

collegiumpharma.com

What Do They Do?

Sells prescription medicines for ADHD and moderate-to-severe pain to pharmaceutical wholesalers, which distribute them to pharmacies and other outlets.

How Do They Make Money?

The company sells its medicines to wholesalers; payment typically arrives 30 to 90 days after the products are delivered.

revenue
SegmentShareRevenue
Belbuca
Sold outright

28%
FY2022: 27%
Xtampza ER
Sold outright

26%
FY2022: 30%
Jornay PM
Sold outright

19%
Nucynta IR
Sold outright

15%
FY2022: 24%
Nucynta ER
Sold outright

10%
FY2022: 16%
Symproic and other
Sold outright
1.9%

Who Are Their Customers?

Collegium sells mainly to wholesalers, which distribute medicines to pharmacies, health care organizations and government agencies. Its field teams call on health care professionals, while market-access staff work on formulary approval and payor contracts.

Customers above 10% of revenue, FY2025
of revenue from three customers (34%, 34%, 29%)
FY2023: 97% from three customers

Do Revenues Turn Into Profits?

Yes. It kept 8 cents of every revenue dollar as net income in FY2025 and turned 42 cents into free cash flow.

Operating income, FY2025
23% of revenue
▲ +6% vs FY2024 ($169.9M, 27%)
Net income, FY2025
8% of revenue
▼ −9% vs FY2024 ($69.2M, 11%)
Free cash flow, FY2025
42% of revenue
▲ +61% vs FY2024 ($203.3M, 32%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +3%
vs $209.4M in Q3 FY2025
Net income
▼ −31%
vs $31.5M in Q3 FY2025
Belbuca share of revenue vs 27.8% in Q3 FY2025
  • Aug 6, 2026 Lowered sales and adjusted earnings guidance The revisions reflect lower-than-expected revenue from authorized generic Nucynta products due to lower net pricing.
  • May 12, 2026 Completed the AZSTARYS acquisition The ADHD prescription medicine expands the company's treatment portfolio.

Growing. Revenue grew 2.8x in 4 years, from $276.9M in FY2021 to $780.6M in FY2025, about 30% a year.

Added ADHD treatment The earlier description covers a pain portfolio; the later description adds ADHD treatment through Jornay PM, expanding the business beyond pain management.

Revenue over time
Belbuca Xtampza ER Jornay PM Nucynta IR Nucynta ER Symproic and other Other Symproic
$1B$500M$0

Who Do They Compete With?

Competes with Vertex Pharmaceuticals

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support